The rising incidence of chronic diseases and increasing advancements in the biopharmaceutical industry are projected to drive the demand for protein expression techniques in the coming years. In addition, advancements in bioprocessing technologies have favored the adoption of protein expression, which has further increased the use of recombinant proteins in therapeutics. According to a white paper article, “Recombinant Proteins for Industrial versus Pharmaceutical Purposes: A Review of Process and Pricing,” published in 2019, over 170 recombinant proteins are used for therapeutic purposes across the world, and the number of such recombinant proteins is expected to rise in the future.
Thermo Fisher Scientific, Inc and Agilent Technologies, Inc. –are Notable Market Players in Protein Expression Market
The production of recombinant protein is a complex, multidisciplinary, and expensive process, and hence it is not yet widely adopted. However, growing awareness has increased the demand for these proteins for human therapeutics. Also, the ongoing developments and evolving healthcare sector are expected to bring advancements in the process of producing recombinant proteins at affordable prices. Furthermore, commercial players seek opportunities to adopt easier, simpler, and automated methods for product development. Therefore, they are continuously striving to develop therapeutic products through economic processes to serve a large population.
The Protein Expression market majorly consists of the players such as companies such Thermo Fisher Scientific, Inc., GenScript, Merck KGaA, Agilent Technologies, Inc., Takara Bio Inc., Bio-Rad Laboratories, Inc., QIAGEN, New England Biolabs, Promega Corporation, and Oxford Expression Technologies Ltd amongst others. The companies have been implementing various strategies that have helped the growth of the company and in turn have brought about various changes in the market. The companies have utilized organic strategies such as launches, expansion, and product approvals. Whereas, the inorganic strategies such as mergers & acquisitions, partnership, collaborations, were widely seen in the Protein Expression market.
Several in organic approaches, such as product launches, and expansion in the Protein Expression market, have resulted in the positive growth of the market. Likewise, inorganic strategies such as mergers & acquisitions, and collaboration have help the company to strengthen its revenue, which allows the company to hold a strong position in the market.
Below is the list of the growth strategies done by the players operating in the Protein Expression market:
| Year | News |
| May-2020 | Thermo Fisher Scientific to Acquired QIAGEN N.V. Benefits of the Transaction are Expands Specialty Diagnostics Portfolio with Attractive Molecular Diagnostics Capabilities, Including Infectious Disease Testing, Complementary Offering Enhances Unique Value Proposition for Life Sciences Customers, Commercial and Geographic Reach Expand Customer Access, Delivers Attractive Financial Benefits through the PPI Business System, Including Proven Integration Approach. |
| Oct-2020 | Merck signed agreements licensing its CRISPR technology to two companies PanCELLa, a cell therapy firm, and Takara Bio USA, Inc., a biotechnology company. Licenses aim to accelerate drug discovery research leading to the development of new therapies, PanCELLa agreement marks Merck’s first CRISPR license for bioproduction, Takara Bio USA agreement gives access to Merck’s CRISPR integration and vector technologies for Takara’s vector products and cell engineering services. |
